Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.

This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

This study found that while the combination of oral propranolol and intradermal injections in guinea pigs led to psoriasiform changes, it did not fully mimic psoriasis.

This chapter reviews adverse effects of anti-anginal and beta-blocker drugs, stating that starting a beta-blocker may temporarily affect driving ability, but it reports no new clinical findings.

Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.

New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that two-thirds of patients with persistent chronic daily headache showed significant improvement with divalproex sodium treatment, although common side effects included weight gain, tremor, hair loss, and nausea.

A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.

Minoxidil can cause hair growth as a side effect.

Metoprolol and propranolol may cause hair loss.

Minoxidil with propranolol and diuretics lowers blood pressure but causes fluid retention and hair growth.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.

This study found that serlopitant may reduce pruritus intensity compared to placebo in patients with chronic pruritus of unknown origin, though evidence is of low certainty and effects on other outcomes are unclear.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This study suggests that finasteride may inhibit the enzyme phenylethanolamine N-methyltransferase, which could contribute to its sexual and psychological side effects.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

This study found that transethosomal gel loaded with propranolol hydrochloride prolonged drug release and increased peak plasma concentration compared to an oral tablet, suggesting a promising alternative for delivery.

This study found that isoliensinine, a natural compound identified from a database, effectively prevented stress-induced hair greying in mice by blocking β-2 adrenergic receptors on melanocyte stem cells in hair follicles.

This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

This article discusses the availability of data from TriNetX for research purposes and reports no new findings.